Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Assessing the diagnostic, prognostic, and therapeutic potential of the somatostatin/cortistatin system in glioblastoma

  • G‐García, Miguel E
  • De la Rosa Herencia, Ana de la Salud
  • Flores Martínez, Álvaro
  • Ortega-Bellido, María
  • Sánchez-Sánchez, Rafael
  • Blanco-Acevedo, Cristóbal
  • Gahete Ortiz, Manuel D.
  • Solivera, Juan
  • Luque, Raúl M.
  • Fuentes-Fayos, Antonio C.
Glioblastoma remains an incurable tumour (median survival: ~ 15 months) and little clinical progress has been made over the past decades. Therefore, identification of novel biomarkers and therapeutic targets is imperative. Targeting the somatostatin/cortistatin-system is considered a successful avenue for treating different tumour pathologies. Thus, we comprehensively characterized (clinically and molecularly) the expression of the somatostatin/cortistatin-system components [ligands and receptors (SSTRs)] using five cohorts of patients and tested the in-vitro therapeutic response of different SSTR-agonists and somatostatin analogs (SSAs) in primary patient-derived glioblastoma cells. A clear downregulation of the whole somatostatin/cortistatin-system (except for SSTR5) in glioblastoma vs. non-tumour brain samples was demonstrated, with high discriminatory capacity. Moreover, poor overall-survival and critical aggressiveness-parameters (i.e., recurrence, IDH1-wildtype and G-CIMP status, classical and mesenchymal GBM-subtypes, EGFR-amplification) were robustly associated with SSTR1/SSTR2 downregulation. Notably, octreotide, pasireotide, and SSTR1/2/5-agonists treatments significantly reduced cell-proliferation in primary patient-derived GBM-cells. Molecularly, antitumour effects of octreotide/pasireotide were exerted through key signalling-factors related to glioblastoma-aggressiveness (i.e., CDKN1A-B/JAK-STAT/NF-κB/TGF-β-pathways). Altogether, this study demonstrated that somatostatin/cortistatin-system is drastically altered in GBM representing a useful prognostic tool, and that SSTR-modulators might represent a potential therapeutic strategy to treat specific subsets of patients with GBM.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

  • Sampedro-Nuñez, Miguel
  • Herrera-Martínez, Aura Dulcinea
  • Ibáñez-Costa, Alejandro
  • Rivero-Cortés, Esther
  • Venegas, Eva
  • Robledo, Mercedes
  • Martínez-Hernández, Rebeca
  • García-Martínez, Araceli
  • Gil, Joan
  • Jordà, Mireia
  • López-Fernández, Judith
  • Gavilán, Inmaculada
  • Maraver, Silvia
  • Marqués-Pamies, Montserrat
  • Cámara, Rosa
  • Fajardo-Montañana, Carmen
  • Valassi, Elena
  • Dios, Elena
  • Aulinas, Anna
  • Biagetti, Betina
  • Álvarez-Escolá, Cristina
  • Araujo-Castro, Marta
  • Blanco, Concepción
  • Paz, de Miguel
  • Villar-Taibo, Rocío
  • Álvarez, Clara V.
  • Gaztambide, Sonia
  • Webb, Susan M.
  • Castaño, Luis
  • Bernabéu, Ignacio
  • Picó, Antonio
  • Gálvez-Moreno, María Ángeles
  • Soto-Moreno, Alfonso
  • Puig-Domingo, Manel
  • Castaño, Justo P.
  • Marazuela, Mónica
  • Luque, Raúl M.
[Introduction] Growth hormone (GH)-secreting pituitary tumors (GHomas) are the most common acromegaly cause. At diagnosis, most of them are macroadenomas, and up to 56% display cavernous sinus invasion. Biomarker assessment associated with tumor growth and invasion is important to optimize their management., [Objectives] The study aims to identify clinical/hormonal/molecular biomarkers associated with tumor size and invasiveness in GHomas and to analyze the influence of pre-treatment with somatostatin analogs (SSAs) or dopamine agonists (DAs) in key molecular biomarker expression., [Methods] Clinical/analytical/radiological variables were evaluated in 192 patients from the REMAH study (ambispective multicenter post-surgery study of the Spanish Society of Endocrinology and Nutrition). The expression of somatostatin/ghrelin/dopamine system components and key pituitary/proliferation markers was evaluated in GHomas after the first surgery. Univariate/multivariate regression studies were performed to identify association between variables., [Results] Eighty percent of patients harbor macroadenomas (63.8% with extrasellar growth). Associations between larger and more invasive GHomas with younger age, visual abnormalities, higher IGF1 levels, extrasellar/suprasellar growth, and/or cavernous sinus invasion were found. Higher GH1 and lower PRL/POMC/CGA/AVPR1B/DRD2T/DRD2L expression levels (P < .05) were associated with tumor invasiveness. Least Absolute Shrinkage and Selection Operator’s penalized regression identified combinations of clinical and molecular features with areas under the curve between 0.67 and 0.82. Pre-operative therapy with DA or SSAs did not alter the expression of any of the markers analyzed except for DRD1/AVPR1B (up-regulated with DA) and FSHB/CRHR1 (down-regulated with SSAs)., [Conclusions] A specific combination of clinical/analytical/molecular variables was found to be associated with tumor invasiveness and growth capacity in GHomas. Pre-treatment with first-line drugs for acromegaly did not significantly modify the expression of the most relevant biomarkers in our association model. These findings provide valuable insights for risk stratification and personalized management of GHomas., This work has been supported by the Spanish Society of Endocrinology and Nutrition (SEEN). The Molecular Registry of Pituitary Adenomas (REMAH) project has been possible thanks to the sponsorship of Novartis and the Fundación SEEN (FSEEN). The research projects of the authors themselves have also contributed to a different extent [Junta de Andalucía (P20_00442; PEER-0048-410), and Spanish Ministry of Science, Innovation and Universities (PID2022-1381850B-I00), Comunidad de Madrid [P2022/BMD-7379], etc.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The telomerase/shelterin system is impaired in acromegaly and Cushing´s disease: Potential pathophysiological relevance

  • García García, Miguel E.
  • Rosa-Herencia, Ana S. de la
  • Gil-Duque, Ignacio
  • Arroyo-Millán, Laura
  • Venegas Moreno, Eva
  • Herrera-Martínez, Aura D.
  • Ortega-Bellido, María
  • Núñez-Santos, Miguel A.
  • Montero-Hidalgo, Antonio J.
  • Gavilán, Inmaculada
  • López-Fernández, Judith
  • Oliva-García, José G.
  • Moreno-Carazo, Alberto
  • Iglesias-Lozano, Irene
  • Ordoñez-Carmona, Marta
  • Dios Fuentes, Elena
  • Remón-Ruiz, Pablo
  • Japón, Miguel A.
  • Solivera, Juan
  • Cano González, David A.
  • Gahete, Manuel D.
  • Flores-Martínez, Álvaro
  • Gálvez-Moreno, María Ángeles
  • Soto-Moreno, Alfonso
  • Fuentes-Fayos, Antonio C.
  • Luque, Raúl M.
Pituitary Tumours (PiTs) present significant challenges in diagnosis and treatments due to their heterogeneity, complex pathophysiology and endocrine comorbidities. Current therapies (i.e., surgery/radiotherapy/pharmacological treatment) frequently become ineffective over time, leading to low quality of life and high recurrence rates. Therefore, identifying alternative medical tools for these rare pathologies is crucial. The alteration of the telomerase/shelterin (TEL/SHEL) molecular complexes has been associated with cancer pathophysiology and progression; however, their role in PiTs remains poorly understood. Herein, we uncovered a profound dysregulation in the expression of key components of the TEL/SHEL systems in growth-hormone, adrenocorticotropic-hormone, and prolactin-hormone producing PiTs [GHomas (n = 50)/ACTHomas (n = 19)/PRLomas (n = 6), respectively] versus non-tumour pituitary tissues (n = 10), and identified critical dysregulated components in GHomas, ACTH, and PRLomas, some of them associated with key clinical features in GHomas (i.e., sinus-invasion/visual-alteration/cephalea, etc.). Presurgery treatment is likely not a confounding variable in the alterations observed in the TEL/SHEL system in PiTs. Moreover, we demonstrated that TEL activity inhibition (using BIBR1532) in primary-patient cell-cultures and cell-line models (GH3/AtT-20) might serve as a potential therapeutic tool by reducing cell-proliferation and stem-cell capacity through the modulation of key oncogenic processes, including GH/ACTH synthesis, cell-cycle, and DNA Damage Repair (DDR) pathways. Notably, we also demonstrated that BIBR1532, in combination with somatostatin-analogues, exerted a synergistic/additive anti-proliferative effect in GH3 and AtT-20 cells. Altogether, we demonstrate a profound TEL/SHEL-associated molecular dysregulation in GHomas and ACTHomas, which could serve as a potential source of novel diagnostic/prognostic biomarkers and therapeutic targets, offering a clinically relevant opportunity worth to be explored in humans., This work was funded by Junta de Andalucía (P20_00442, PI-0117–2025, DGP_PIDI_2024_00134, BIO-0139, FPS-0032–2021, A1–0034–2023, DGP_POST_2024_00710), Foundation of the Spanish Society of Endocrinology and Nutrition (FSEEN), Spanish Ministry of Science, Innovation and Universities (PID2022–1381850B-I00, FPU20/03954, FPU21/00857, FPU23/02246), Instituto de Salud Carlos III (ISCIII, CD24_00240) and CIBERobn. CIBER is an initiative of ISC-III, “Ministerio de Sanidad, Servicios Sociales e Igualdad”, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathophysiological and translational implications of the dysregulation of molecular machineries controlling RNA metabolism in thyrotropinomas

  • García García, Miguel E.
  • Flores-Martínez, Álvaro
  • Arroyo-Milán, Laura
  • Venegas Moreno, Eva
  • Díaz-Perdigones, Cristina M.
  • Maraver, Silvia
  • Cano González, David A.
  • Arráez, Miguel A.
  • Japón, Miguel A.
  • Martínez-Fuentes, Antonio J.
  • Soto-Moreno, Alfonso
  • Fuentes-Fayos, Antonio C.
  • Herrera-Martínez, Aura D.
  • Luque, Raúl M.
The contribution of post-transcriptional regulation remains largely unexplored in thyrotropin-secreting pituitary tumors (TSHomas), a rare endocrine pathology responsible for inappropriate TSH secretion and central hyperthyroidism. We investigated the TSHoma post-transcriptional regulatory landscape by analyzing components of molecular machineries controlling RNA metabolism [spliceosome/RNA-exosome/nonsense-mediated decay (NMD)], their associations with clinical parameters, and the impact of their pharmacological inhibition in TSHoma cells. A drastic dysregulation of multiple components of spliceosome [spliceosome (SF3B2/U2AF35/PRPF40A) and splicing factors (e.g., SRP30C/EIF4A3/DDX1/TRA2B/HNRNNF…)], RNA-Exosome (e.g., DIS3/DIS3L/PABPN1), and NMD [e.g., PABPC1, and NMD-canonical targets (DDIT3/GADD45B/MAFF/PDRG1/ATF4/ATF3)] was found in TSHomas vs. non-tumor pituitaries with some of these alterations associated with relevant clinical features (e.g., tumor size, TSHB/fT4-levels). Moreover, we demonstrate a clear antiproliferative action of spliceosome/RNA-Exosome/NMD inhibitors in primary patient-derived TSHoma cells. Overall, a clinically relevant spliceosome/RNA-Exosome/NMD-associated molecular dysregulation and antiproliferative actions of these machineries’ inhibition are demonstrated in TSHomas, highlighting a potential source of novel diagnostic/prognostic biomarkers and therapeutic tools in TSHomas., This work was funded by Junta de Andalucía (P20_00442, PI-0117-2025, DGP_PIDI_2024_00134, DGP_POST_2024_00272, BIO-0139), Foundation of the Spanish Society of Endocrinology and Nutrition (FSEEN), Spanish Ministry of Science, Innovation and Universities (PID2022-1381850B-I00, FPU20/03954), and CIBEROBN., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

MiR-7 inhibits progression of glioblastoma by impairing autophagy resolution, energy metabolism and ECM remodeling

  • Torrecilla Parra, Marta
  • Pardo Marqués, Virginia
  • Fuentes Fayos, Antonio C.
  • G. García, Miguel E.
  • Fernández de Frutos, Mario
  • López Aceituno, José L.
  • Puigdueta, Cristina
  • Zamora, Carmen
  • Pérez García, Ana
  • Aranda Gómez, Juan Francisco
  • Busto, Rebeca
  • Gahete, Manuel D.
  • Luque, Raúl M.
  • Ramírez, Cristina M.
Background. Due to the poor prognosis of patients suffering malignant brain tumors such as glioblastoma multiforme (GBM), the search for new therapeutic strategies with more efficacy and higher survival rate is of utmost urgency. Growing evidence suggests that alterations in autophagy and metabolism critically contribute to the pathogenesis and progression of GBM. In this context, microRNAs are known to regulate autophagy and associated cellular functions, which point them as promising therapeutic candidates. We previously established the role of miR-7 in regulating relevant metabolic pathways related to insulin signaling and cholesterol homeostasis. Methods, Bioinformatics analysis was performed to identify miR-7 target genes potentially involved in the regulation of metabolism and cellular processes related to GBM. Ectopic expression of miR-7 was assessed to investigate its role in macroautophagy and energy metabolism. In vivo, miR-7 levels were restored in a mouse GBM xenograft model to evaluate its potential therapeutic effect in already established tumors. Additional mechanistic approaches, including transcriptomics, bioinformatics, and histopathological analyses, indicate that miR-7 modifies the tumor phenotype by altering key genes involved in extracellular matrix (ECM) remodeling in vivo. Results. Herein, we unveiled new conceptual and functional pathophysiological avenues in GBM, with potential therapeutic implications, by demonstrating a novel dual role of miR-7 on the regulation of metabolism, through the impairment of the mitochondrial function and glycolysis, and autophagy, by inducing the initiation process through the regulation of PI3K/AKT/mTORC1 signaling, while blocking later stages via posttranscriptional inhibition of two key SNARE proteins, STX17 and SNAP29. Furthermore, in vivo studies using a preclinical model showed that miR-7 overexpression in already established GBM tumors promotes a significant inhibition of tumor size and progression and replicates the metabolic defects found in vitro. Moreover, our novel findings indicate that miR-7 modifies the tumor phenotype by promoting alterations in its mechanism of extracellular matrix remodeling in vivo. Conclusion. Altogether, our study provides solid, convincing evidence demonstrating that miR-7 might be used as a promising therapeutic target for GBM, paving the way to explore its potential as novel biomarker and actionable target candidate for this lethal cancer.